63204-27-3

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-chlorobenzyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one is used as a potential candidate for the development of new drugs due to its unique structure and functional groups that may contribute to various biological and pharmacological activities.
Further research and studies are required to explore the full potential and applications of 5-(4-chlorobenzyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one in the field of medicinal chemistry.

Upstream product

• 7116-36-1 ethyl 3-(4-chlorophenyl)propanoate 
• 17356-08-0 thiourea 
• 109-94-4 formic acid ethyl ester 
• 24393-52-0 ethyl (E)-3-(4-chlorophenyl)prop-2-enoate 
• 6048-06-2 ethyl-p-chlorocinnamate 
• 1615-02-7 p-chlorocinnamic acid 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 63204-28-4 5-(4-chlorobenzyl)-2-methylthiopyrimid-4-one 
• 63204-14-8 5-(4-chloro-benzyl)-2-[2-(5-methyl-1⁽³⁾H-imidazol-4-ylmethylsulfanyl)-ethylamino]-1⁽³⁾H-pyrimidin-4-one 

Relevant academic research and scientific papers

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.

Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2- hydroxyethoxy)methyl]-5-benzyluracils

A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine- induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 μM), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3- alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 μM, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 μM.